4 transcripts
SDGR
Earnings call transcript
NASDAQ
2024 Q2
31 Jul 24
options tell us about that?
Thanks, Mike. I'll take the first question and then hand it over to Geoff to either add to the response to the first question
SDGR
Earnings call transcript
NASDAQ
2024 Q1
1 May 24
, showing monotherapy responses in the range of 28% ORR and combination activity -- in combination with BTK, giving you around 30% or -- we also know
SDGR
Earnings call transcript
NASDAQ
2023 Q4
28 Feb 24
at greater than 50-fold lower concentrations than the benchmark molecule, which has shown clinical responses in indolent or aggressive lymphoma and CLL
SDGR
Earnings call transcript
NASDAQ
2023 Q2
2 Aug 23
of pharma experience and will be responsible for clinical development and regulatory strategy for our pipeline of wholly-owned programs, and we look forward
- Prev
- 1
- Next